Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Lymphoma, Large B-Cell, Diffuse Clinical Trial

— R-Pola-Glo  

Official title:

A Prospective Multicenter Phase 2 Study of the Chemotherapy-light Combination of Intravenous Rituximab With the Antibody-drug Conjugate Polatuzumab Vedotin and the Bispecific Antibody Glofitamab in Previously Untreated Aggressive B-cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOP

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05798156
• Other study ID #: R-Pola-Glo
• Secondary ID: 2022-003398-51GL
• Status: Recruiting
• Phase: Phase 2
• Start date: March 20, 2023
• Est. completion date: September 30, 2028

Study information

• Verified date: December 2023
• Source: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
• Contact: Björn Chapuy, Univ.-Prof. Dr. med.
• Phone: +49 30 450 613423
• Email: bjoern.chapuy[@]charite.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In the present trial the chemotherapy- light treatment concept R-Pola-Glo will be evaluated that combines the anti-CD20 antibody rituximab (R) with the ADC polatuzumab vedotin (Pola) and the (BiMabs) glofitamab (Glo) in elderly and/or medical unfit and previously untreated patients with aggressive B-cell lymphoma. The outcome and feasibility data obtained here will be used for further clinical development of this new chemolight triple combination.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: September 30, 2028
• Est. primary completion date: September 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 61 Years and older

Eligibility

Inclusion Criteria:

1. Patient has provided written informed consent and is able and willing to comply with the study protocol and protocol mandated hospitalizations according to ICH and local regulations.

2. Patient is above 60 years of age

3. Patient is not eligible for a fully dosed R-CHOP

4. Patient has histologically confirmed aggressive B-cell lymphoma.

5. Patient has at least one measurable FDG PET-positive lymphoma manifestation; defined as lesional maximum FDG uptake higher than the maximum FDG uptake in unaffected liver parenchyma as measured in a reference volume-of-interest with >10 mL

6. Baseline biopsy material is available for central review.

7. Female patients considered as women of childbearing potential (WOCBP, see section 5.2.7 for definition) and male patients with female partners considered as WOCBP must:

1. agree to either remain completely abstinent (refrain from heterosexual intercourse) or to use at least one effective contraceptive methods that results in a failure rate of < 1% per year

2. refrain from donating ova (female patients) or donating sperm (male patients)

3. in case of male patients with pregnant female partners, remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures such as a condom to avoid exposing the embryo.

8. Patient did not receive any prior lymphoma therapy.

9. Patient has an ECOG performance status of = 2.

10. Patient has with treatment a life expectancy (in the opinion of the investigator) of at least 12 weeks.

11. Patient has adequate liver function

12. Patient as adequate hematological function

13. Patient has adequate renal function

14. Patients has negative serologic and/or polymerase chain reaction (PCR) test results for:

• Acute or chronic hepatitis B (HBV) infection.

• Hepatis C virus (HCV) and human immunodeficiency virus (HIV)

15. Patient has no active SARS-CoV-2 infection.

Exclusion Criteria:

Medical conditions:

1. Patient with chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) (including CD20+ ALL), lymphoblastic lymphoma, Richter's transformation, Burkitt lymphoma.

2. Patient = 60 years

3. Patient with known active infection, or reactivation of a latent infection, whether bacterial (e.g., tuberculosis), viral (including, but not limited to severe pneumonia, COVID-19, Epstein-Barr virus [EBV], cytomegalovirus [CMV], hepatitis B, hepatitis C, and HIV], fungal, mycobacterial, or other pathogens (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics (for IV antibiotics this pertains to completion of last course of antibiotic treatment) within 4 weeks prior to study enrollment.

4. Patient with current > Grade 1 peripheral neuropathy.

5. Patient with history of confirmed progressive multifocal leukoencephalopathy (PML).

6. Patient with history of leptomeningeal disease.

7. Patient with current or history of CNS lymphoma.

8. Patient with current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease with exceptions.

9. Patient with another invasive malignancy in the last 2 years (with the exception of basal cell carcinoma and tumors deemed by the Investigator to be of low likelihood for recurrence), with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate 90%), such as adequately-treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.

10. Patient with significant or extensive history of cardiovascular disease (such as New York Heart Association (NYHA) Class = II cardiac disease, congestive heart failure, myocardial infarction or cerebrovascular accident within the past 3 months, unstable arrhythmias, or unstable angina or history of multiple cardiovascular events) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm).

11. Patient with active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis (see addendum for a more comprehensive list of autoimmune diseases and immune deficiencies), with exceptions.

12. Patient with uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).

13. Patient with history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic.

Prior/Concomitant Therapy:

14. Patient received treatment with any other standard anti-cancer radiotherapy/chemotherapy including investigational therapy (defined as treatment for which there is currently no regulatory authority approved indication) within 4 weeks or five times the elimination half-life of the product, whichever is longer, prior to study enrollment.

15. Patient with prior solid organ transplantation.

16. Patient with prior allogeneic stem cell transplantation.

17. Patient with prior treatment with targeted therapies (e.g., tyrosine kinase inhibitors, systemic immunotherapeutic/immunostimulating agents, including, but not limited to, CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, radio-immunoconjugates, antibody-drug conjugates, immune/cytokines, and monoclonal antibodies) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to study enrollment.

18. Patient with toxicities from prior anti-cancer therapy including immunotherapy that did not resolve to = Grade 1 except for alopecia, endocrinopathy managed with replacement therapy and stable vitiligo.

19. Patient with any history of immune related = Grade 3 AE except for endocrinopathy managed with replacement therapy.

20. Patient with ongoing corticosteroid use 25 mg/day of prednisone or equivalent within 4 weeks prior and during study treatment.

21. Patient with treatment with systemic immunosuppressive medication (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with exceptions.

22. Patient who received administration of a live, attenuated vaccine within 4 weeks prior to study enrollment infusion or anticipation that such a live, attenuated vaccine will be required during the study or within 5 months after the last dose of study treatment.

Other Exclusions:

23. Patient with history of illicit drug or alcohol abuse within 12 months prior to screening, in the Investigator's judgment.

24. Patient with history of severe allergic anaphylactic reactions to chimeric or humanized monoclonal antibodies or recombinant antibody-related fusion proteins.

25. Patient with known hypersensitivity to Chinese hamster ovary (CHO) cell products or to any component of the rituximab, obinutuzumab, polatuzumab vedotin and/or glofitamab formulation and/or to the contrast agents used in the study.

26. Female patient is pregnant or breast feeding. Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study treatment.

27. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.

28. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].

29. Patients who are dependent on the sponsor, the investigator or the trial site.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Large B-Cell, Diffuse

Intervention

Drug:
• Glofitamab
Glofitamab is a fully humanized, engineered monoclonal bivalent antibody of the IgG1 isotype.
• Rituximab
Rituximab is a genetically engineered chimeric mouse/human anti-CD20 monoclonal antibody
• Obinutuzumab
Obinutuzumab is a fully humanized, glycoengineered type II monoclonal antibody of the IgG1 isotype that binds to an epitope on CD20
• Polatuzumab vedotin
Polatuzumab vedotin is an antibody-drug-conjugate that contains a humanized IgG1 anti-CD79b monoclonal antibody (MCDS4409A) and a potent anti-mitotic agent (MMAE) linked through a protease-cleavable linker.

Locations

Country	Name	City	State
Austria	Kepler Universitätsklinikum	Linz
Austria	Ordensklinikum Linz - Barmherzige Schwestern	Linz
Austria	Ordensklinikum Linz - Elisabethinen	Linz
Austria	Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität	Salzburg
Austria	Univ. Klinikum St. Pölten	St. Pölten
Austria	AKH Meduni Wien	Wien
Austria	Hanusch Krankenhaus	Wien
Germany	Charité - Universitätsmedizin Berlin	Berlin
Germany	HELIOS Klinikum Berlin-Buch	Berlin
Germany	Medizinisches Universitätsklinikum Knappschaftskrankenhaus Bochum	Bochum
Germany	Klinikum Chemnitz	Chemnitz
Germany	Universitätsklinikum Erlangen	Erlangen
Germany	Ev. Klinikum Essen-Mitte	Essen
Germany	Universitätsklinikum Halle	Halle
Germany	University Hospital Jena	Jena
Germany	Universitätsklinikum Schleswig-Holstein Campus Kiel	Kiel
Germany	Universitätsklinikum Leipzig	Leipzig
Germany	Klinikum Ludwigshafen	Ludwigshafen
Germany	TU München (rechts des Isar)	München
Germany	Unversitätsklinikum Münster	Münster
Germany	Ortenauklinikum Offenburg-Kehl	Offenburg
Germany	Universitätsklinikum Regensburg	Regensburg
Germany	Kreiskliniken Reutlingen	Reutlingen
Germany	Universitätsklinikum Würzburg	Würzburg

Sponsors (7)

Lead Sponsor	Collaborator
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Arbeitsgemeinschaft medikamentoese Tumortherapie, Charite University, Berlin, Germany, Hoffmann-La Roche, Roche Pharma AG, University of Salzburg, Zentrum für Klinische Studien Leipzig

Countries where clinical trial is conducted

Austria,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Rate of minimal residual disease (MRD)-negative patients after end of target phase and at end of treatment		54 months
Other	Duration of molecular remission for MRD negative patients		54 months
Primary	1 year progression-free survival (PFS) rate	defined as the time from the day of inclusion until disease progression (PD) or relapse after complete remission (CR), or death due to any cause, whichever occurs first	12 months
Secondary	Event-free survival (EFS)	defined as the time from the day of inclusion until progressive disease or relapse after complete remission, initiation of subsequent systemic antilymphoma treatment, radiation of single PET-CT positive lesions or death due to any cause, whichever occurs first.	54 months
Secondary	Overall survival (OS)	defined as the time from the day of inclusion until death due to any cause	54 months
Secondary	Response rate at different timepoints	Response rates after 2 cycles (during target dose phase), 6 cycles (end of target dose phase before start of consolidation phase) and 12 cycles (end of treatment following completion of consolidation phase). i.e., complete remission (CR) rate, partial remission (PR) rate, overall remission rate (ORR: CR+PR), stable disease (SD) rate and progressive disease (PD) rate	6 weeks, 18 weeks, 36 weeks
Secondary	Relapse rate	defined as the number of patients with relapse, divided by the number of patients achieving C	54 months
Secondary	Conversion rate of PR to CR	defined as the number of patients achieving mCR at the end of study treatment (including consolidation phase) divided by the number of patients achieving PR after end of target dose phase (before start of consolidation phase)	54 months
Secondary	Duration of response (DoR)	defined as the time from documentation of CR until relapse or lymphoma associated death without documented relapse	54 months
Secondary	Rate and type of adverse events (AEs) and serious adverse events (SAEs)		54 months
Secondary	Rate of secondary malignancies	defined as the number of patients with secondary malignancies divided by the number of analyzable patients	54 months
Secondary	Treatment-related death rate	defined as the number of treatment related deaths during therapy or up to 2 months after the end of study treatment, but before the start of further treatment, divided by the number of analyzable patients	54 months
Secondary	Protocol adherence	number and duration of R-Pola-Glo cycles, number and duration of glofitamab maintenance, cumulative and relative doses of rituximab, glofitamab and polatuzumab.	54 months
Secondary	Patient-reported outcomes for quality of life (QoL): EORTC QLQ-C30	measured by EORTC QLQ-C30 (a 30-item questionnaire developed by the European Organisation for Research and Treatment of Cancer). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.	54 months
Secondary	Patient-reported outcomes for quality of life (QoL): FACT-Lym	measured by FACT-Lym (Functional Assessment of Cancer Therapy - Lymphoma; scores from 0 - 4; The higher the score, the better the QOL)	54 months